SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Community sentiment remains heavily polarized as traders weigh the potential market impact of ongoing geopolitical tensions and new economic sanctions against Iran, while others focus on speculative talk of an upcoming merger catalyst.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing selling pressure as investors track launch schedule updates and institutional activity while the stock navigates a broader sector-wide pullback. Community sentiment remains polarized, with long-term investors highlighting partnerships and growth catalysts while others express frustration over management transparency regarding satellite deployments.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing community attention as investors debate its long-term potential as a payment collateral utility versus its prolonged downward price action. Discussions center on whether the project is at a major accumulation point or facing structural decline, with participants closely monitoring legislative developments and institutional interest in crypto payment rails.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

UAMY is trending after a sharp sell-off sparked by significantly lowered full-year revenue guidance and a Q2 earnings miss, with investors pointing to lower antimony market prices and execution delays. The community remains polarized, with some bulls emphasizing the company's long-term monopoly status and strategic importance to domestic defense, while others express frustration over management's communication and the volatility of its growth narrative.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as investors navigate pre-earnings uncertainty and broader semiconductor sector weakness, with community discussions polarized between those expecting a 'lights out' blowout quarter and skeptics citing concerns over circular financing and geopolitical trade risks. Despite the volatility, many participants are viewing the pullback as a buying opportunity ahead of key data-center and AI infrastructure updates scheduled for this week.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is surging as community members discuss a new multibillion-dollar cash pool while Bitcoin trends higher, sparking intense debate between bulls expecting a short squeeze and bears skeptical of ongoing share dilution. The stock remains a focal point for retail traders who are actively tracking its correlation with Bitcoin's momentum and the company's aggressive capital allocation strategy.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is seeing significant volatility after the FDA placed a clinical hold on its RGX-121 gene therapy due to asymptomatic spinal MRI findings, leading the company to delay its BLA resubmission. While the news prompted a sharp stock decline, the retail community remains divided, with some investors calling the selloff an overreaction and emphasizing the company's other key pipeline programs.

Reinvent Technology Partners Y operates as a blank check company. The company was founded by Reid Hoffman, Mark Pincus and Michael N. Thompson, Jr. in 2020 and is headquartered in New York, NY.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is facing heightened volatility as investors weigh strong operational milestones, such as the launch of its second-generation trucks and a growing list of commercial partnerships, against broad market pressure and periodic block sales from major institutional stakeholders. While the community remains divided between those capitalizing on dip-buying opportunities and those concerned about the company's long-term path to profitability, many long-term shareholders are focused on the company's ability to scale autonomous freight operations by 2027.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is experiencing bullish momentum as the company expands its oncology and immunology portfolio, driven by positive data for its HIV treatments and strong market interest in its cell therapy advancements. The community is actively discussing Gilead's strategic acquisitions and the durability of its core HIV franchise, positioning the stock as a key player in current institutional healthcare rotation.

CF Acquisition Corp. VI operates as a blank check company. It focuses on the search of companies in the financial services, healthcare, real estate services, technology and software industries. The company was founded on April 17, 2020 and is headquartered in New York, NY.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is surging as investors react to a massive 13.7 billion dollar cloud services contract that validates the company's expansion into AI and GPU infrastructure. Community sentiment remains highly bullish, with many focusing on the potential for a significant short squeeze given the substantial short float and steady accumulation patterns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.read more...

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals, Inc. Profit Climbs In Q2

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) revealed earnings for its second quarter that Increases, from the same period last year...

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -5.88% and -46.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI Pharmaceuticals Inc

ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors

Equity

Neutral Sentiment

Beat EPS and revenue 

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Nvidia ($NVDA) reports Q2 earnings Wednesday with Wall Street expecting roughly $91.7 billion in revenue — about 80% year-over-year growth — and EPS near $2.08. What do you expect in terms of revenue and EPS? Vote and explain your reasoning in the comments.

What do you expect from Nvidia ($NVDA) earnings on Wednesday?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANIP ANI Pharmaceuticals Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest ANIP News